Drug: lorazepam Quarter: 2016Q3
Total Records: 465 Number of Pages: 24
DRUGNAME | PT | EventCount |
---|---|---|
LORAZEPAM. | Maternal exposure timing unspecified | 1 |
LORAZEPAM. | Melanosis | 1 |
LORAZEPAM. | Mental disorder | 1 |
LORAZEPAM. | Mental status changes | 1 |
LORAZEPAM. | Metabolic encephalopathy | 1 |
LORAZEPAM. | Metamorphopsia | 1 |
LORAZEPAM. | Monocyte count decreased | 1 |
LORAZEPAM. | Mood altered | 1 |
LORAZEPAM. | Movement disorder | 1 |
LORAZEPAM. | Muscle rigidity | 1 |
LORAZEPAM. | Muscle spasms | 1 |
LORAZEPAM. | Muscle tightness | 1 |
LORAZEPAM. | Muscular weakness | 1 |
LORAZEPAM. | Musculoskeletal discomfort | 1 |
LORAZEPAM. | Mutism | 1 |
LORAZEPAM. | Myocardial infarction | 1 |
LORAZEPAM. | Myoclonus | 1 |
LORAZEPAM. | Myopia | 1 |
LORAZEPAM. | Neonatal respiratory distress syndrome | 1 |
LORAZEPAM. | Neoplasm | 1 |
Total Records: 465 Number of Pages: 24